Naska

Nasus Pharma is a clinical-stage biopharmaceutical company specializing in the development of needle-free, intranasal powder formulations of established life-saving medicines. The company leverages a proprietary powder technology designed to enhance the intranasal absorption of various molecules, providing a faster and more convenient alternative to traditional injections. Its lead program, Flynas, is an intranasal epinephrine powder being developed for the emergency treatment of anaphylaxis, which has demonstrated superior absorption kinetics compared to standard auto-injectors in clinical trials. Nasus Pharma's pipeline also includes intranasal versions of ondansetron for chemotherapy-induced nausea and other molecules targeting respiratory and central nervous system disorders.